Three-Drug attack on Tough-to-Treat liver cancer
NCT ID NCT07081633
Summary
This study is testing a combination of three medicines—durvalumab, tremelimumab, and lenvatinib—as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug approach can better control the cancer's growth and spread. It will involve about 114 participants and closely monitor how well the treatment works and its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBeijing, 100029, China
-
Research Site
RECRUITINGBeijing, 100044, China
-
Research Site
RECRUITINGBeijing, 100142, China
-
Research Site
RECRUITINGChengdu, 610078, China
-
Research Site
RECRUITINGChongqing, 400016, China
-
Research Site
RECRUITINGGuangzhou, 510060, China
-
Research Site
RECRUITINGGuangzhou, 510095, China
-
Research Site
RECRUITINGGuangzhou, 510120, China
-
Research Site
RECRUITINGGuangzhou, 510515, China
-
Research Site
RECRUITINGHangzhou, 310022, China
-
Research Site
RECRUITINGHefei, 230022, China
-
Research Site
RECRUITINGJinan, 250021, China
-
Research Site
RECRUITINGNanjing, 210009, China
-
Research Site
RECRUITINGNanjing, 210029, China
-
Research Site
RECRUITINGNingbo, 315010, China
-
Research Site
NOT_YET_RECRUITINGShanghai, 200032, China
-
Research Site
RECRUITINGShanghai, 200438, China
-
Research Site
NOT_YET_RECRUITINGTaiyuan, 030001, China
-
Research Site
RECRUITINGTianjin, 300060, China
-
Research Site
RECRUITINGWenzhou, 325000, China
-
Research Site
RECRUITINGWuhan, 430030, China
-
Research Site
RECRUITINGXiamen, 361004, China
-
Research Site
RECRUITINGZhengzhou, 450052, China
-
Research Site
RECRUITINGNew Territories, Hong Kong
Conditions
Explore the condition pages connected to this study.